ABSTRACT
Background Recent three-dimensional optical (3DO) imaging advancements have provided more accessible, affordable, and self-operating opportunities for assessing body composition. 3DO is accurate and precise with respect to clinical measures made by dual-energy X-ray absorptiometry (DXA). However, the sensitivity for monitoring body composition change over time with 3DO body shape is unknown.
Objective To evaluate 3DO’s ability to monitor body composition changes across multiple intervention studies.
Methods A retrospective analysis was performed using intervention studies on healthy adults that were complimentary to the cross-sectional study, Shape Up! Adults. Each participant received a DXA (Hologic Discovery/A system) and 3DO (Fit3D ProScanner) scan at baseline and follow-up. 3DO meshes were digitally registered and reposed using Meshcapade to standardize the vertices and pose. Using an established statistical shape model, each 3DO mesh was transformed into principal components (PCs), which were used to predict whole-body and regional body composition values using published equations. Body composition changes (follow-up minus baseline) were compared to DXA with linear regression.
Results The analysis included 133 participants (45 females) in six studies. The mean (SD) length of follow-up was 13 (5) weeks, range 3-23 weeks. Agreement between 3DO and DXA (R2) for changes in total fat mass (FM), total fat-free mass (FFM), and appendicular lean mass, respectively, were 0.86, 0.73, and 0.70 with RMSEs of 1.98 kg, 1.58 kg, and 0.37 kg in females, and 0.75, 0.75, and 0.52 with RMSEs of 2.31 kg, 1.77 kg, and 0.52 kg in males. Further adjustment with demographic descriptors improved the 3DO change agreement to changes observed with DXA.
Conclusions As compared to DXA, 3DO was highly sensitive in detecting body shape changes over time. The 3DO method was sensitive enough to detect even small changes in body composition during intervention studies. The safety and accessibility of 3DO allows users to self-monitor on a frequent basis throughout interventions.
Competing Interest Statement
SBH reports his role on the Medical Advisory Boards of Tanita Corporation, Amgen, and Medifast; he is also an Amazon Scholar.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03637855
Funding Statement
Phases of this study were funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH R01 DK R01DK109008), National Institute of Aging (R21AG058181), the US Army Medical Research and Development Command, Military Operational Medicine Research Program Grant W81XWH-19-C-0162. Supported in part by an appointment to the U.S. Army Research Institute of Environmental Medicine administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Army Medical Research and Development Command.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided informed consent. The study protocol was approved by the Institutional Review Boards (IRBs) at Pennington Biomedical Research Center (IRB study #2016-053), University of California, San Francisco (IRB #15-18066), and the University of Hawaii Office of Research Compliance (UH ORC, CHS #2017-01018)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Phases of this study were funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH R01 DK R01DK109008), National Institute of Aging (R21AG058181), the US Army Medical Research and Development Command, Military Operational Medicine Research Program Grant W81XWH-19-C-0162. Supported in part by an appointment to the U.S. Army Research Institute of Environmental Medicine administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Army Medical Research and Development Command.
Clinical Trials Number Shape Up! Adults (NCT03637855, https://clinicaltrials.gov/ct2/show/NCT03637855)
Macronutrients and Body Fat Accumulation: A Mechanistic Feeding Study (NCT03394664, https://clinicaltrials.gov/ct2/show/NCT03394664)
Resistance Exercise and Low-Intensity Physical Activity Breaks in Sedentary Time to Improve Muscle and Cardiometabolic Health (NCT03771417, https://clinicaltrials.gov/ct2/show/NCT03771417)
Time Restricted Eating on Weight Loss (NCT03393195, https://clinicaltrials.gov/ct2/show/NCT03393195)
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations (NCT04120363, https://clinicaltrials.gov/ct2/show/NCT04120363)
Conflicts of Interest SBH reports his role on the Medical Advisory Boards of Tanita Corporation, Amgen, and Medifast; he is also an Amazon Scholar.
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Army or the Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement of approval of the products or services of these organizations.
All other authors have no disclosures.
This is an updated version following peer-review suggestions and comments in AJCN.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- 3DO
- (three-dimensional optical)
- ALM
- (appendicular lean mass)
- ALMI
- (appendicular lean mass index)
- CV
- (coefficient of variation)
- DXA
- (dual-energy X-ray absorptiometry)
- FM
- (fat mass)
- FFM
- (fat-free mass)
- LSC
- (least significant change)
- PCA
- (principal component analysis)
- PCs
- (principal components)
- VAT
- (visceral adipose tissue)
